Portfolio Lab

Corcept Therapeutics Inc

  • Stock
  • Ticker CORT
  • ISIN US2183521028
  • Nasdaq

Health care · Pharmaceuticals · USA

$63.62 −2.09%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Corcept Therapeutics Inc since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

CORTGlobal equities (VT)

$10,000 grew to $68,043. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −71.9% in 03/2026, measured from the peak in 03/2025. It took 16 months to get back to the old peak.

1-year return
−15.2%
5-year return p.a.
+22.7%
10-year return p.a.
+21.1%
Volatility p.a.
64.0%
Largest decline
−71.9%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue182157194208202165256340
Gross profit179155191203200162252336
Operating income253.427104.5-5041115
EBITDA263.927114.2-4942116
Net income3121352024-3243127
Earnings per share0.250.170.290.160.20-0.300.361.01
Balance sheet
Total assets8418468028248378158891,034
Liabilities161163166192189177183200
Equity680683636632648638706834
Cash1289010312512010911199
Cash flow
Operating cash flow604.8445438-1734143
Capital expenditure-0.1-0.1-0.10.0-0.1-0.2-2.5-0.7
Free cash flow604.7445438-1731142

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2017 at +148.8%, weakest 2025 at −30.9%. 5 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
3 Nov 2026$1.01
29 Jul 2026$0.36
30 Apr 2026−$0.30
24 Feb 2026$0.20
4 Nov 2025$0.16
31 Jul 2025$0.29
5 May 2025$0.17
26 Feb 2025$0.25
30 Oct 2024$0.41
29 Jul 2024$0.32
1 May 2024$0.25
15 Feb 2024$0.28

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€6.3bn
Market cap in trading currency
$6.96bn
Enterprise value
$6.59bn
P/E
50.1
P/S
7.23
P/B
8.35
EV/Sales
6.84
EV/EBITDA
58.3
Earnings yield
2.0%
FCF yield
2.8%

Results (last four quarters)

Revenue
$964m
Gross profit
$950m
EBITDA
$113m
Net income
$162m
Earnings per share
$1.27
Revenue per share
$8.81
Revenue growth
+64.0%
Earnings growth
+544.6%

Profitability

Gross margin
98.5%
Operating margin
11.5%
Net margin
16.8%
Return on equity
22.1%
Return on assets
15.7%

Balance sheet and cash flow

Cash
$371m
Cash per share
$3.39
Financial debt
–
Debt/equity %
–
Current ratio
3.00
Book value per share
$7.62
Operating cash flow
$198m
Free cash flow
$195m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
0%
Ex-dividend date
–

Shares and trading

Shares outstanding
109m
Volume
1.09m
Avg. volume 3 months
1.26m
Relative volume
0.9

Price and technicals

Price
$63.62
1 day
−2.1%
52-week high
$123.57
52-week low
$32.15
Distance to 52-week high
−48.5%
Distance to 52-week low
+97.9%
Distance to 50-day line
−35.8%
Distance to 200-day line
−17.6%
RSI (14)
21
Volatility 1M
87.9%

Performance

1 week
−12.8%
1 month
−40.8%
3 months
−48.4%
6 months
+5.6%
YTD
+82.8%
1 year
−16.4%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has CORT performed since 11/2016?

$10,000 grew to $68,043 by 20 Nov 2026, which is +21.1% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is CORT?

Volatility was 64.0% per year, measured on monthly returns. The largest decline from a peak was −71.9%, with the low in 03/2026.

How does CORT compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, CORT returned +21.1% at 64.0%. The correlation of monthly returns was 0.18; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Corcept Therapeutics Inc (CORT): Return and risk